export default {
	en: {
		app: {
			name: 'ASH Microsite 2023',
		},
		home: {
			title: 'Our Pipeline',
			footer: {
				jobCode: 'UNB-EM-0239 December 2023',
				copyright: '&copy; 2023 Regeneron Pharmaceuticals, Inc. All Rights Reserved.',
				copy: 'This information is intended for investigators interested in active clinical trials. The uses of all agents described herein are investigational and have not been evaluated by any regulatory authority.',
			},
		},
		titles: {
			trials: {
				lymphoma: 'Lymphoma',
				myeloma: 'Myeloma',
				'classical-hematology': 'Classical Hematology',
				'solid-tumor': 'Solid Tumor',
			},
			cards: {
				'olympia-2':
					'<strong>OLYMPIA-2</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Chemotherapy',
				'olympia-5':
					'<strong>OLYMPIA-5</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Chemotherapy',
				'olympia-1':
					'<strong>OLYMPIA-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
				'olympia-3':
					'<strong>OLYMPIA-3</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> + Chemotherapy',
				'olympia-4':
					'<strong>OLYMPIA-4</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
				'elm-2':
					'<strong>ELM-2</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
				'elm-1':
					'<strong>ELM-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span>',
				'athena-1':
					'<strong>ATHENA-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> REGN5837 <span class="ui-one-word">(CD22xCD28 bispecific)</span>',
				'clio-1':
					'<strong>CLIO-1</strong> Odronextamab <span class="ui-one-word">(CD20xCD3 bispecific)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',

				orchid: '<strong>ORCHID</strong> Non-interventional real-world experience',
				flora: '<strong>FLORA</strong> Non-interventional real-world experience',

				'linker-mm3':
					'<strong>LINKER-MM3</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
				'linker-mm4':
					'<strong>LINKER-MM4</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
				'linker-mm1':
					'<strong>LINKER-MM1</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
				'linker-smm1':
					'<strong>LINKER-SMM1</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span>',
				'linker-mm2':
					'<strong>LINKER-MM2</strong> Linvoseltamab <span class="ui-one-word">(BCMAxCD3 bispecific)</span> + Other Cancer Treatments',
				nct05673967:
					'<strong>NCT05673967</strong> <span class="ui-one-word">Non-interventional</span> <span class="ui-one-word">real-world</span> experience',

				'access-1':
					'<strong>ACCESS-1</strong> Pozelimab <span class="ui-one-word">(C5 monoclonal antibody)</span> Cemdisiran <span class="ui-one-word">(C5 RNAi)<sup>†</sup></span>',
				nct04409080:
					'<strong>NCT04409080</strong> REGN7257 <span class="ui-one-word">(IL2RG blocking antibody)</span>',
				nct05618808:
					'<strong>NCT05618808</strong> REGN9933 <span class="ui-one-word">(Factor XI antibody)</span>',
				nct04601051:
					'<strong>NCT04601051</strong> <span class="ui-one-word">NTLA-2001</span> <span class="ui-one-word">(TTR Gene editing)<sup>††</sup></span>',
				nct05481333:
					'<strong>NCT05481333</strong> REGN7999 <span class="ui-one-word">(TMPRSS6 antagonist)</span>',
				'honey-b':
					'<strong>HONEY-B</strong> <span class="ui-one-word">Lead-in,</span> <span class="ui-one-word">non-interventional</span> <span class="ui-one-word">real-world</span> study',

				'pd-1-monoclonal-p3':
					'Adjuvant Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'pd-1-monoclonal-p2':
					'Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'pd-1-monoclonal-p1':
					'Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'pd-1-monoclonal-non-interventional':
					'Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',

				'solid-tumor-lung-cancer-01':
					'Fianlimab <span class="ui-one-word">(LAG-3 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-lung-cancer-02':
					'Fianlimab <span class="ui-one-word">(LAG-3 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span> + Chemotherapy',
				'solid-tumor-lung-cancer-03':
					'Ipilimumab <span class="ui-one-word">(CTLA-4 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span> + <span class="ui-one-word">Platinum-based</span> Doublet Chemotherapy',
				'solid-tumor-lung-cancer-04':
					'REGN5093 <span class="ui-one-word">(METxMET biparatopic)</span>',
				'solid-tumor-lung-cancer-05':
					'<span class="ui-one-word">REGN5093-M114</span> (METxMET antibody-drug conjugate)',

				'solid-tumor-melanoma-01':
					'Fianlimab <span class="ui-one-word">(LAG-3 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-melanoma-02':
					'Fianlimab <span class="ui-one-word">(LAG-3 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',

				'solid-tumor-prostate-01':
					'REGN4336 <span class="ui-one-word">(PSMAxCD3 bispecific)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-prostate-02':
					'REGN5678 <span class="ui-one-word">(PSMAxCD28 bispecific)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',

				'solid-tumor-ovarian-01':
					'Ubamatamab <span class="ui-one-word">(MUC16xCD3 bispecific)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-ovarian-02':
					'REGN5668 <span class="ui-one-word">(MUC16xCD28 bispecific)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span> Ubamatamab <span class="ui-one-word">(MUC16xCD3 bispecific)</span>',
				'solid-tumor-ovarian-03':
					'REGN5668 <span class="ui-one-word">(MUC16xCD28 bispecific)</span> + Ubamatamab <span class="ui-one-word">(MUC16xCD3 bispecific)</span>',

				'solid-tumor-multiple-tumors-01':
					'REGN7075 <span class="ui-one-word">(EGFRxCD28 bispecific)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-multiple-tumors-02':
					'Vidutolimod <span class="ui-one-word">(TLR9 agonist)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-multiple-tumors-03':
					'Fianlimab <span class="ui-one-word">(LAG-3 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-multiple-tumors-04':
					'Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span> <span class="ui-one-word">+ Other Agent</span>',
				'solid-tumor-multiple-tumors-05':
					'REGN6569 <span class="ui-one-word">(GITR monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
				'solid-tumor-multiple-tumors-06':
					'89Zr-DFOREGN5054 <span class="ui-one-word">(CD8 monoclonal)</span> Cemiplimab <span class="ui-one-word">(PD-1 monoclonal)</span>',
			},
			cardsSection: {
				'skin-cancer': 'non-melanoma skin cancer',
				'lung-cancer': 'Non-Small Cell Lung Cancer ',
				melanoma: 'Melanoma',
				prostate: 'Prostate Cancer',
				ovarian: 'Ovarian Cancer',
				'multiple-tumors': 'multiple tumors',
			},
			tags: {
				'olympia-2': 'untreated or relapsed/refractory follicular lymphoma',
				'olympia-5': 'Relapsed/refractory follicular lymphoma and marginal zone lymphoma',
				'olympia-1': 'previously untreated follicular lymphoma',
				'olympia-3':
					'untreated diffuse large <span class="ui-one-word">b-cell</span> lymphoma',
				'olympia-4':
					'Relapsed/Refractory DIFFUSE LARGE <span class="ui-one-word">B-CELL</span> LYMPHOMA',
				'elm-2':
					'relapsed/refractory <span class="ui-one-word">B-cell</span> non-Hodgkin Lymphoma',
				'elm-1': '<span class="ui-one-word">B-CELL</span> MALIGNANCIES',
				'athena-1':
					'aggressive <span class="ui-one-word">B-cell</span> non-hodgkin lymphoma',
				'clio-1':
					'Relapsed/refractory aggressive <span class="ui-one-word">b-cell</span> <span class="ui-one-word">non-hodgkin</span> lymphoma',

				orchid: 'Relapsed/refractory diffuse large b-cell lymphoma',
				flora: 'Relapsed/refractory follicular lymphoma',

				'linker-mm3': 'relapsed/refractory Multiple Myeloma',
				'linker-mm4': 'previously untreated symptomatic multiple myeloma',
				'linker-mm1': 'relapsed/refractory Multiple Myeloma',
				'linker-smm1': 'high-risk smoldering multiple myeloma',
				'linker-mm2': 'relapsed/refractory Multiple Myeloma',
				nct05673967: 'relapsed/refractory Multiple Myeloma',

				'access-1': 'PAROXYSMAL NOCTURNAL HEMOGLOBINURIA',
				nct04409080: 'SEVERE APLASTIC ANEMIA',
				nct05618808: 'THROMBOTIC DISORDERS',
				nct04601051: 'TRANSTHYRETIN AMYLOIDOSIS',
				nct05481333: 'Transfusion-dependent iron overload',
				'honey-b': 'Hemophilia B',

				'pd-1-monoclonal-p3':
					'<span class="ui-one-word">high-risk</span> cutaneous squamous cell carcinoma',
				'pd-1-monoclonal-p2': 'stage II to IV cutaneous squamous cell carcinoma',
				'pd-1-monoclonal-p1': 'cutaneous squamous cell carcinoma or basal cell carcinoma',
				'pd-1-monoclonal-non-interventional':
					'<span class="ui-one-word">NON-MELANOMA</span> SKIN CANCER',

				'solid-tumor-lung-cancer-01':
					'advanced <span class="ui-one-word">non-small</span> cell lung cancer with <span class="ui-one-word">PD-L1</span> expression &gt; 50%',
				'solid-tumor-lung-cancer-02':
					'advanced <span class="ui-one-word">non-small</span> cell lung cancer',
				'solid-tumor-lung-cancer-03':
					'advanced or metastatic <span class="ui-one-word">non-small</span> cell lung cancer',
				'solid-tumor-lung-cancer-04':
					'<span class="ui-one-word">MET-altered</span> advanced <span class="ui-one-word">non-small</span> cell lung cancer',
				'solid-tumor-lung-cancer-05':
					'<span class="ui-one-word">MET-overexpressing</span> <span class="ui-one-word">non-small</span> cell lung cancer',

				'solid-tumor-melanoma-01': 'advanced or metastatic melanoma',
				'solid-tumor-melanoma-02':
					'adjuvant use in completely resected <span class="ui-one-word">high-risk</span> melanoma',

				'solid-tumor-prostate-01':
					'metastatic <span class="ui-one-word">castration-resistant</span> prostate CANCER',
				'solid-tumor-prostate-02':
					'metastatic <span class="ui-one-word">castration-resistant</span> prostate CANCER',

				'solid-tumor-ovarian-01':
					'<span class="ui-one-word">platinum-resistant</span> ovarian CANCER',
				'solid-tumor-ovarian-02': 'recurrent ovarian CANCER',
				'solid-tumor-ovarian-03': 'Ovarian',

				'solid-tumor-multiple-tumors-01': 'advanced solid tumors',
				'solid-tumor-multiple-tumors-02': 'advanced/metastatic tumors',
				'solid-tumor-multiple-tumors-03': 'advanced malignancies',
				'solid-tumor-multiple-tumors-04': 'advanced malignancies (Japanese patients)',
				'solid-tumor-multiple-tumors-05': 'advanced solid tumors',
				'solid-tumor-multiple-tumors-06': 'advanced and metastatic solid tumors',
			},
		},
		misc: {
			clinicalTrials: 'Clinical trials',
			explore: 'Explore',
			back: 'Back',
			backToTrials: 'Back To Trials',
			phase: 'Phase',
			nonInterventional: 'Non-Interventional',
			seeTrialInfo: 'See Trial Info',
			seeClincialGov: 'Visit ClinicalTrials.gov',
			noPdf: 'No Trial card PDF found. Please try again later.',
			close: 'Close',
		},
		trials: {
			overlay: {
				lymphoma: 'LEARN ABOUT ODRONEXTAMAB',
				myeloma: 'LEARN ABOUT linvoseltamab',
			},
			footer: {
				meta: 'Odronextamab is an investigational drug and has not been fully evaluated by any regulatory authority.',
				jobCode: 'UNB-EM-0239. December 2023',
				enclosed:
					'The enclosed materials are being provided in response to your unsolicited request and are for your information only. The product discussed herein is an investigational agent and has not been fully evaluated or approved by the US Food and Drug Administration or any other regulatory agency worldwide. Reactive Use Only.',
				copyright: '&copy; 2023 Regeneron Pharmaceuticals, Inc. All Rights Reserved.',
				copy: 'The uses of all agents described herein are investigational and have not been evaluated by any regulatory authority. This information is intended for investigators interested in active clinical trials.',
				'classical-hematology':
					'<sup>†</sup> In collaboration with Alnylam Pharmaceuticals.<br><sup>††</sup> In collaboration with Intellia.',
			},
		},
	},
};
